A clinical randomized controlled trial of pazufloxacin injection in treatment of bacterial infection in 111 patients
SHI Yi,XIAO Yong-ying,SU Xin,SHAO Hai-feng,SONG Yong,ZHAO Bei-lei,CAO E-hong,XIAO Xin-wu,WANG Wei-ping,XIAO Wei,WANG Mao-fen,SUN Li-hua,ZHANG Hui
DOI: https://doi.org/10.3969/j.issn.1007-7669.2005.12.004
2005-01-01
Abstract:AIM: To evaluate the efficacy and safety of domestic pazufloxacin for injection in the treatment of bacterial infections. METHODS: A multi-center, single blind, parallel-group, randomized controlled study of pazufloxacin was conducted among 227 individuals with bacterial infections (113 with respiratory tract infections, 114 with urinary tract infections). They were randomized either to treatment group (111 patient, treated with pazufloxacin, 300 mg, iv, gtt, bid, for 7-10 d) or control group (116 patient, treated with levofloxacin, 200 mg, iv, gtt, bid, for 7-10 d). RESULTS: The toltal clinical effective rate was 97.4 % (110/113) in treatment group and 91.5 % (108/118) in control group. There was no significant difference of recovery rate(72.6 % vs 67.8 %, P>0.05), efficacy rate(97.4 % vs 91.5 %, P>0.05) and bacterial eradication rate( 99 % vs 98.0 %, P>0.05) between two groups. The incidence rate of adverse reactions was 12.0 % in the treatment group and 12.6 % in the control group (P>0.05). No severe adverse reactions were found. CONCLUSION: Pazufloxacin for injection is an effective and safe antibiotic in the treatment of bacterial infections in respiratory tract and urinary tract.